Peter Lönn
Science for Life Laboratory
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Peter Lönn.
Nature Biotechnology | 2014
Bryan R. Meade; Khirud Gogoi; Alexander S. Hamil; Caroline Palm-Apergi; Arjen van den Berg; Jonathan C. Hagopian; Aaron D. Springer; Akiko Eguchi; Apollo D. Kacsinta; Connor F Dowdy; Asaf Presente; Peter Lönn; Manuel Kaulich; Naohisa Yoshioka; Edwige Gros; Xian-Shu Cui; Steven F. Dowdy
RNA interference (RNAi) has great potential to treat human disease. However, in vivo delivery of short interfering RNAs (siRNAs), which are negatively charged double-stranded RNA macromolecules, remains a major hurdle. Current siRNA delivery has begun to move away from large lipid and synthetic nanoparticles to more defined molecular conjugates. Here we address this issue by synthesis of short interfering ribonucleic neutrals (siRNNs) whose phosphate backbone contains neutral phosphotriester groups, allowing for delivery into cells. Once inside cells, siRNNs are converted by cytoplasmic thioesterases into native, charged phosphodiester-backbone siRNAs, which induce robust RNAi responses. siRNNs have favorable drug-like properties, including high synthetic yields, serum stability and absence of innate immune responses. Unlike siRNAs, siRNNs avidly bind serum albumin to positively influence pharmacokinetic properties. Systemic delivery of siRNNs conjugated to a hepatocyte-specific targeting domain induced extended dose-dependent in vivo RNAi responses in mice. We believe that siRNNs represent a technology that will open new avenues for development of RNAi therapeutics.
Expert Opinion on Drug Delivery | 2015
Peter Lönn; Steven F. Dowdy
Introduction: Macromolecular therapeutics, including enzymes, transcription factors, siRNAs, peptides and large synthetic molecules, can potentially be used to treat human diseases by targeting intracellular molecular pathways and modulating biological responses. However, large macromolecules have no ability to enter cells and require delivery vehicles. Protein transduction domains (PTDs), also known as cell-penetrating peptides (CPPs), are a diverse class of peptides that can deliver macromolecules into cells. Areas covered: In this review, we cover the uptake and usage of arginine-rich PTDs/CPPs (TAT-PTD, Penetratin/Antp and 8R). We review the endocytosis-mediated uptake of these peptides and highlight three important steps: i) cell association; ii) internalization and iii) endosomal escape. We also discuss the array of different cargos that have been delivered by cationic PTDs/CPPs as well as cellular processes and biological responses that have been modulated. Expert opinion: PTDs/CPPs have shown great potential to deliver otherwise undeliverable macromolecular therapeutics into cells for experimentation in cell culture and in animal disease models in vivo. Moreover, over 25 clinical trials have been performed predominantly using the TAT-PTD. However, more work is still needed. Endosomal escape and target-cell specificity remain two of the major future challenges.
Journal of Experimental Medicine | 2015
Larry Mansouri; Lesley-Ann Sutton; Viktor Ljungström; Sina Bondza; Linda Arngården; Sujata Bhoi; Jimmy Larsson; Diego Cortese; Antonia Kalushkova; Karla Plevová; Erin Young; Rebeqa Gunnarsson; Elin Falk-Sörqvist; Peter Lönn; Alice F. Muggen; Xiao-Jie Yan; Brigitta Sander; Gunilla Enblad; Karin E. Smedby; Gunnar Juliusson; Chrysoula Belessi; Johan Rung; Nicholas Chiorazzi; Jonathan C. Strefford; Anton W. Langerak; Šárka Pospíšilová; Frederic Davi; Mats Hellström; Helena Jernberg-Wiklund; Paolo Ghia
Mansouri et al. applied targeted deep sequencing to identify mutations within NF-κB core complex genes in CLL. NFKBIE, the gene encoding the inhibitory IκBε molecule, was most frequently mutated, especially in poor-prognostic subgroups of CLL. The authors show that NFKBIE mutations were associated with significantly reduced IkBε expression and p65 inhibition, ultimately leading to NF-κB activation and a more aggressive disease.
Scientific Reports | 2016
Peter Lönn; Apollo D. Kacsinta; Xian-Shu Cui; Alexander S. Hamil; Manuel Kaulich; Khirud Gogoi; Steven F. Dowdy
Bioactive macromolecular peptides and oligonucleotides have significant therapeutic potential. However, due to their size, they have no ability to enter the cytoplasm of cells. Peptide/Protein transduction domains (PTDs), also called cell-penetrating peptides (CPPs), can promote uptake of macromolecules via endocytosis. However, overcoming the rate-limiting step of endosomal escape into the cytoplasm remains a major challenge. Hydrophobic amino acid R groups are known to play a vital role in viral escape from endosomes. Here we utilize a real-time, quantitative live cell split-GFP fluorescence complementation phenotypic assay to systematically analyze and optimize a series of synthetic endosomal escape domains (EEDs). By conjugating EEDs to a TAT-PTD/CPP spilt-GFP peptide complementation assay, we were able to quantitatively measure endosomal escape into the cytoplasm of live cells via restoration of GFP fluorescence by intracellular molecular complementation. We found that EEDs containing two aromatic indole rings or one indole ring and two aromatic phenyl groups at a fixed distance of six polyethylene glycol (PEG) units from the TAT-PTD-cargo significantly enhanced cytoplasmic delivery in the absence of cytotoxicity. EEDs address the critical rate-limiting step of endosomal escape in delivery of macromolecular biologic peptide, protein and siRNA therapeutics into cells.
Journal of Molecular Biology | 2015
Karin Grannas; Linda Arngården; Peter Lönn; Magdalena Mazurkiewicz; Andries Blokzijl; Agata Zieba; Ola Söderberg
The Hippo pathway plays a crucial role in growth control, proliferation and tumor suppression. Activity of the signaling pathway is associated with cell density sensing and tissue organization. Furthermore, the Hippo pathway helps to coordinate cellular processes through crosstalk with growth-factor-mediated signaling pathways such as TGFβ. Here we have examined the localization of interactions between proteins of the Hippo pathway (YAP/TAZ) and TGFβ (Smad2/3) signaling pathway by using in situ proximity ligation assays. We investigated the formation of protein complexes between YAP/TAZ and Smad2/3 and examined how these interactions were affected by TGFβ stimulation and cell density in HaCaT keratinocytes and in Smad4-deficient HT29 colon cancer cells. We demonstrate that TGFβ induces formation of YAP/TAZ-Smad2/3 complexes in HaCaT cells. Under sparse cell conditions, the complexes were detected to a higher degree and were predominantly located in the nucleus, while under dense culture conditions, the complexes were fewer and mainly located in the cytoplasm. Surprisingly, we could not detect any YAP/TAZ-Smad2/3 complexes in HT29 cells. To examine if Smad4 deficiency was responsible for the absence of interactions, we treated HaCaT cells with siRNA targeting Smad4. However, we could still observe complex formation in the siRNA-treated cells, suggesting that Smad4 is not essential for the YAP-Smad2/3 interaction. In conclusion, this study shows localized, density-dependent formation of YAP/TAZ-Smad2/3 complexes in HaCaT cells and provides evidence supporting a crosstalk between the Hippo and the TGFβ signaling pathways.
Journal of Controlled Release | 2014
Nicholas A. Peppas; Ruth Duncan; Gary E. Wnek; Allan S. Hoffman; Guang Hui Gao; Sung Wan Kim; Doo Sung Lee; Michael Hadjiargyrou; Elka Touitou; Denize Ainbinder; Russell J. Mumper; Alain Rolland; Takuro Niidome; Vinod Labhasetwar; Shi Liu; Guangyuan Zhou; Yubin Huang; Zhigang Xie; Xiabin Jing; Noemi Csaba; María J. Alonso; Omar A. Ali; David J. Mooney; Peter Lönn; Steven F. Dowdy; Si Shen Feng; Jinming Gao; Eun Seong Lee; Kun Na; You Han Bae
Abstract To celebrate the success of the Journal of Controlled Release and the research covered in the journal, here we highlight some of the most cited research articles in the history of the journal. Based on the literature search in Google Scholar in July 2013, we identified ~30 research articles that have received most number of citations. Authors of these articles were invited to provide a commentary on these articles. This compilation of commentaries gives a historical perspective and current status of research covered in these articles.
Molecular Therapy | 2012
Caroline Palm-Apergi; Peter Lönn; Steven F. Dowdy
Cell-penetrating peptides (CPPs), also referred to as peptide transduction domains (PTDs), are polypeptide domains that can enter many, if not most, cell types. CPP/PTDs mediate transduction into cells of a wide range of cargos that otherwise lack bioavailability, such as peptides, proteins, antisense oligonucleotides, and small interfering RNAs. CPP/PTDs are thus being studied extensively as delivery agents for molecular therapies, and a variety of transducing peptides have now been identified, including both naturally occurring domains and synthetically derived sequences comprising polycationic or amphipathic residues.1 Although much progress has been made in understanding the endocytotic mechanisms by which CPP/PTDs enter cells,1 several important unanswered questions remain. In an upcoming issue of Molecular Therapy, Hirose and colleagues report a study in which they reexamined the direct membrane transduction mechanism of CPP/PTDs using highly sensitive imaging techniques and well-controlled experimental systems.2 The study reinforces the notion that CPP/PTDs enter cells by endocytosis (macropinocytosis), but it also highlights the significance of the specific peptide and cargo conditions that drive membrane deformations required for concomitant, low-level nonendocytotic uptake.
Nucleic Acids Research | 2015
Manuel Kaulich; Yeon J. Lee; Peter Lönn; Aaron D. Springer; Bryan R. Meade; Steven F. Dowdy
Gene knockout strategies, RNAi and rescue experiments are all employed to study mammalian gene function. However, the disadvantages of these approaches include: loss of function adaptation, reduced viability and gene overexpression that rarely matches endogenous levels. Here, we developed an endogenous gene knockdown/rescue strategy that combines RNAi selectivity with a highly efficient CRISPR directed recombinant Adeno-Associated Virus (rAAV) mediated gene targeting approach to introduce allele-specific mutations plus an allele-selective siRNA Sensitive (siSN) site that allows for studying gene mutations while maintaining endogenous expression and regulation of the gene of interest. CRISPR/Cas9 plus rAAV targeted gene-replacement and introduction of allele-specific RNAi sensitivity mutations in the CDK2 and CDK1 genes resulted in a >85% site-specific recombination of Neo-resistant clones versus ∼8% for rAAV alone. RNAi knockdown of wild type (WT) Cdk2 with siWT in heterozygotic knockin cells resulted in the mutant Cdk2 phenotype cell cycle arrest, whereas allele specific knockdown of mutant CDK2 with siSN resulted in a wild type phenotype. Together, these observations demonstrate the ability of CRISPR plus rAAV to efficiently recombine a genomic locus and tag it with a selective siRNA sequence that allows for allele-selective phenotypic assays of the gene of interest while it remains expressed and regulated under endogenous control mechanisms.
Trends in Biochemical Sciences | 2017
Peter Lönn; Ulf Landegren
The well-oiled machinery of the cellular proteome operates via variable expression, modifications, and interactions of proteins, relaying genomic and transcriptomic information to coordinate cellular functions. In recent years, a number of techniques have emerged that serve to identify sets of proteins acting in close proximity in the course of orchestrating cellular activities. These proximity-dependent assays, including BiFC, BioID, APEX, FRET, and isPLA, have opened up new avenues to examine protein interactions in live or fixed cells. We review herein the current status of proximity-dependent in situ techniques. We compare the advantages and limitations of the methods, underlining recent progress and the growing importance of these techniques in basic research, and we discuss their potential as tools for drug development and diagnostics.
New Biotechnology | 2017
Felipe Marques Souza de Oliveira; Stefan Mereiter; Peter Lönn; Benjamin Siart; Qiujin Shen; Johan Heldin; Doroteya Raykova; Niclas G. Karlsson; Karol Polom; Franco Roviello; Celso A. Reis; Masood Kamali-Moghaddam
Post-translational modifications (PTMs) regulate protein activities to help orchestrate and fine-tune cellular processes. Dysregulation of PTMs is often related with disorders and malignancies, and may serve as a precise biomarker of disease. Developing sensitive tools to measure and monitor low-abundant PTMs in tissue lysates or serum will be instrumental for opening up new PTM-based diagnostic avenues. Here, we investigate the use of solid-phase proximity ligation assay (SP-PLA) for detection of different PTMs. The assay depends on the recognition of the target protein molecule and its modification by three affinity binders. Using antibodies and lectins, we applied the method for detection of glycosylated CD44 and E-Cadherin, and phosphorylated p53 and EGFR. The assay was found to have superior dynamic range and limit of detection compared to standard ELISAs. In summary, we have established the use of SP-PLA as an appropriate method for sensitive detection of PTMs in lysates and sera, which may provide a basis for future PTM-based diagnostic and prognostic biomarkers.